PharmGen Science, Inc. (KRX:004720)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,325.00
-40.00 (-0.92%)
Last updated: Jun 23, 2025

PharmGen Science Revenue

PharmGen Science had revenue of 42.88B KRW in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 171.66B, down -0.02% year-over-year. In the year 2024, PharmGen Science had annual revenue of 171.29B with 2.70% growth.

Revenue (ttm)
171.66B
Revenue Growth
-0.02%
P/S Ratio
0.45
Revenue / Employee
759.55M
Employees
226
Market Cap
77.27B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024171.29B4.51B2.70%
Dec 31, 2023166.78B15.85B10.50%
Dec 31, 2022150.93B41.06B37.38%
Dec 31, 2021109.87B13.25B13.72%
Dec 31, 202096.61B1.48B1.55%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,898.69B
Celltrion 3,662.23B
ALTEOGEN 151.65B
Yuhan 2,114.76B
SK Biopharmaceuticals 578.00B
HLB Co., Ltd. 74.64B
PharmaResearch 392.31B
Peptron 4.30B
Revenue Rankings